Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  US Nuclear Corp.    UCLE


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

US Nuclear Corp. Discusses The Future of Neural Stimulation Technology with The Stock Day Podcast

09/24/2020 | 09:05am EST

Phoenix, Arizona--(Newsfile Corp. - September 24, 2020) - The Stock Day Podcast welcomed US Nuclear Corp. (OTC Pink: UCLE) ("the Company"), a radiation and chemical detection holding company specializing in the development, manufacturing, and sales of radiation and chemical detection instrumentation. CEO of the Company, Bob Goldstein, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's partner, Grapheton, and its development of neural stimulation technology. "Grapheton is the only company in the world that makes biocompatible electrodes, and also biocompatible smart chips that can be implanted under the skin or in the scalp," explained Goldstein. "Grapheton is also the only company that is constantly measuring the changing chemistry in the brain," he continued. "With the brain-computer interface, the idea is that it will be doing two-way discussions with the brain to assist and augment with its many functions."

Goldstein then shared that the Company currently owns 49.5% of Grapheton, and is eager to continue working with them on the development of their neural stimulation technology, which can be used to treat pain and depression. "It's just so exciting," said Goldstein.

Jolly then asked about the differences between Elon Musk's Neuralink technology and Grapheton's brain-computer interface. "They're both startup companies, they're both in the same space of neuroscience and brain communication, but Neuralink is focused on the big idea of directly linking the brain to computers and the internet," explained Goldstein. "Grapheton is much more practical and near-term," said Goldstein. He then shared that Grapheton's technology can be used to combat a wide range of conditions, including many serious problems: addiction, pain, depression. Diseases: Parkinsons, Alzheimers. And organ control including: heart, kidney, pancreas and bladder malfunction.

The conversation then turned to the future of neural stimulation technology. "If we want to live long, healthy, happy lives, we're just gonna have to learn how to talk to the brain and learn how the brain works, and how to assist and augment it when there's a problem," said Goldstein, before elaborating on the potential this technology represents for the medical industry.

Jolly asked about the impact Grapheton could have on the Company across the next two to three quarters. Goldstein explained that Grapheton is currently in the process of raising $2 million to fund their current projects, and may begin to produce revenue in the near future.

"Investors want to be doing something good," said Goldstein. "They want to feel that they're helping the world move forward and this is where it's at. This is the last frontier in the health world," closed Goldstein.

To hear Bob Goldstein's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7690320-us-nuclear-corp-discusses-the-future-of-neural-stimulation-technology-with-the-stock-day-podcast

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About US Nuclear Corp.

US Nuclear Corp is a radiation and chemical detection holding company specializing in the development and manufacturing and sales of radiation and chemical detection instrumentation. Through three operating divisions (Technical Associates (TA), Overhoff Technology (OTC), and Electronic Control Concepts (ECC), US Nuclear Corp. harbors more than 100 years of combined experience in supplying top of the line instrumentation to any industry utilizing radionuclides. This includes nuclear power plants, national laboratories, government agencies, homeland security, military, universities and schools, research companies, hospitals, medical and dental centers, energy companies, weapons facilities, first responders, local governments, and manufacturing plants.

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company's website at www.usnuclearcorp.com


US Nuclear Corp. (UCLE)
Robert I. Goldstein, President, CEO, and Chairman
(818) 883 7043
Email: info@usnuclearcorp.com

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64556

© Newsfilecorp 2020
All news about US NUCLEAR CORP.
11/18US NUCLEAR : Management's Discussion and Analysis of Financial Condition and Res..
11/02US NUCLEAR : and Grapheton Brain Implants to Help Immobilized Patients
11/02US Nuclear and Grapheton Brain Implants to Help Immobilized Patients
10/19US NUCLEAR : Secures Its Position at Bioelectronics Startup Grapheton
10/19US Nuclear Secures Its Position at Bioelectronics Startup Grapheton
10/06US NUCLEAR : Tritium Monitor Market Soars Due to Construction of $20+ Billion IT..
10/06US NUCLEAR : Tritium Monitor Market Soars Due to Construction of $20+ Billion IT..
09/24US Nuclear Corp. Discusses The Future of Neural Stimulation Technology with T..
09/24US NUCLEAR CORP : . Announces Second Quarter 2020 Results
09/24US Nuclear Corp. Announces Second Quarter 2020 Results
More news
Financials (USD)
Sales 2019 3,54 M - -
Net income 2019 -3,16 M - -
Net cash 2019 0,10 M - -
P/E ratio 2019 -4,28x
Yield 2019 -
Capitalization 5,35 M 5,35 M -
EV / Sales 2018 2,02x
EV / Sales 2019 3,85x
Nbr of Employees 20
Free-Float 48,4%
Duration : Period :
US Nuclear Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Robert I. Goldstein Chairman, President & Chief Executive Officer
Richard Landry COO & Director-Investor Relations
Rachel Boulds Chief Financial Officer & Secretary
Michael G. Hastings Director
Dell Williamson Director
Sector and Competitors